Impact of a recent chemotherapy on the duration and intensity of the norepinephrine support during septic shock

Shock

Volumn 39, Issue 2, 2013, Pages 138-143

  Schnell, David ^a,b   Besset, Sébastien ^a,b   Lengliné, Etienne ^a,b   Maziers, Nicolas ^a,b   Zafrani, Lara ^a,b   Reuter, Danielle ^a,b   Moreau, Anne Sophie ^a,b   Canet, Emmanuel ^a,b   Lemiale, Virginie ^a,b   Azoulay, Élie ^a,b  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Cancer; chemotherapy; hematological malignancy; intensive care unit; septic shock

Indexed keywords

AMINOGLYCOSIDE; ANTINEOPLASTIC AGENT; BETA LACTAM ANTIBIOTIC; NORADRENALIN; VANCOMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGE; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; COLORECTAL TUMOR; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; ESOPHAGUS TUMOR; FEMALE; HODGKIN DISEASE; HUMAN; INTENSIVE CARE; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; MORTALITY; MYELODYSPLASTIC SYNDROME; MYELOMA; NONHODGKIN LYMPHOMA; PROSTATE TUMOR; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; SEPTIC SHOCK; TREATMENT DURATION;

AGED; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE; MALE; MIDDLE AGED; NEOPLASMS; NOREPINEPHRINE; RENAL REPLACEMENT THERAPY; RESPIRATION, ARTIFICIAL; SHOCK, SEPTIC; TIME-TO-TREATMENT; VASOCONSTRICTOR AGENTS;

EID: 84872980798     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3182810a0f     Document Type: Article

References (35)

1. Azoulay E, Alberti C, Bornstain C, Leleu G, Moreau D, Recher C, Chevret S, Le Gall JR, Brochard L, Schlemmer B: Improved survival in cancer patients requiring mechanical ventilatory support: impact of noninvasive mechanical ventilatory support. Crit Care Med 29(3):519-525, 2001.
2. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lym-phoma. N Engl J Med 346(4):235-242, 2002.
3. Darmon M, Thiery G, Ciroldi M, Porcher R, Schlemmer B, Azoulay E: Should dialysis be offered to cancer patients with acute kidney injury? Intensive Care Med 33(5):765-772, 2007.
4. Larche J, Azoulay E, Fieux F, Mesnard L, Moreau D, Thiery G, Darmon M, Le Gall JR, Schlemmer B: Improved survival of critically ill cancer patients with septic shock. Intensive Care Med 29(10):1688-1695, 2003.
5. Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN, Wolff L, Uckun FM, Gaynon PS: Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 338(23):1663-1671, 1998.
6. Brenner H, Gondos A, Arndt V: Recent major progress in long-term cancer patient survival disclosed by modeled period analysis. J Clin Oncol 25(22): 3274-3280, 2007.
7. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, et al.: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7(5):379-391, 2006.
8. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, et al.: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352(24):2487-2498, 2005.
9. Annane D, Bellissant E, Cavaillon JM: Septic shock. Lancet 365(9453): 63-78, 2005.
10. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, Weiss YG, Benbenishty J, Kalenka A, Forst H, et al.: Hydrocortisone therapy for patients with septic shock. N Engl J Med 358(2):111-124, 2008.
11. Zuber B, Tran TC, Aegerter P, Grimaldi D, Charpentier J, Guidet B, Mira JP, Pene F: Impact of case volume on survival of septic shock in patients with malignancies. Crit Care Med 40(1):55-62, 2012.
12. Legrand M, Max A, Peigne V, Mariotte E, Canet E, Debrumetz A, Lemiale V, Seguin A, Darmon M, Schlemmer B, et al.: Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med 40(1):43-49, 2012.
13. Dhainaut JF, Claessens YE, Janes J, Nelson DR: Underlying disorders and their impact on the host response to infection. Clin Infect Dis 41(Suppl 7): S481-S489, 2005.
14. Levy B, Collin S, Sennoun N, Ducrocq N, Kimmoun A, Asfar P, Perez P, Meziani F: Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside. Intensive Care Med 36(12):2019-2029, 2010.
15. Merx MW, Weber C: Sepsis and the heart. Circulation 116(7):793-802, 2007.
16. Shan K, Lincoff AM, Young JB: Anthracycline-induced cardiotoxicity. Ann Intern Med 125(1):47-58, 1996.
17. Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA, Ewer MS: Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109(25): 3122-3131, 2004.
18. Chow AY, Chin C, Dahl G, Rosenthal DN: Anthracyclines cause endothe-lial injury in pediatric cancer patients: a pilot study. J Clin Oncol 24(6): 925-928, 2006.
19. Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH: Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 24(3):484-490, 2006.
20. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 29(4): 530-538, 2003.
21. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR: Infectious Diseases Society of America: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):e56-e93, 2011.
22. Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S: Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multi-center, prospective study. Working group on Bsepsis-related problems[of the European Society of Intensive Care Medicine. Crit Care Med 26(11): 1793-1800, 1998.
23. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A: Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11(2):R31, 2007.
24. Karvunidis T, Chvojka J, Lysak D, Sykora R, Krouzecky A, Radej J, Novak I, Matejovic M: Septic shock and chemotherapy-induced cytopenia: effects on microcirculation. Intensive Care Med 38(8):1336-1344, 2012.
25. Vandijck DM, Benoit DD, Depuydt PO, Offner FC, Blot SI, Van Tilborgh AK, Nollet J, Steel E, Noens LA, Decruyenaere JM: Impact of recent intravenous chemotherapy on outcome in severe sepsis and septic shock patients with hematological malignancies. Intensive Care Med 34(5):847-855, 2008.
26. Azoulay E, Soares M, Darmon M, Benoit D, Pastores S, Afessa B: Intensive care of the cancer patient: recent achievements and remaining challenges. Ann Intensive Care 1(1):5, 2011. ePub 23 March 2011.
27. Afessa B, Tefferi A, Hoagland HC, Letendre L, Peters SG: Outcome of recipients of bone marrow transplants who require intensive-care unit support. Mayo Clin Proc 67(2):117-122, 1992.
28. Benoit DD, Vandewoude KH, Decruyenaere JM, Hoste EA, Colardyn FA: Outcome and early prognostic indicators in patients with a hematologic malignancy admitted to the intensive care unit for a life-threatening complication. Crit Care Med 31(1):104-112, 2003.
29. Lecuyer L, Chevret S, Thiery G, Darmon M, Schlemmer B, Azoulay E: The ICU trial: a new admission policy for cancer patients requiring mechanical ventilation. Crit Care Med 35(3):808-814, 2007.
30. Soares M, Azoulay E: Critical care management of lung cancer patients to prolong life without prolonging dying. Intensive Care Med 35(12):2012-2014, 2009.
31. Soares M, Salluh JI, Spector N, Rocco JR: Characteristics and outcomes of cancer patients requiring mechanical ventilatory support for 924 hrs. Crit Care Med 33(3):520-526, 2005.
32. Soares M, Caruso P, Silva E, Teles JM, Lobo SM, Friedman G, Dal Pizzol F, Mello PV, Bozza FA, Silva UV, et al.: Characteristics and outcomes of patients with cancer requiring admission to intensive care units: a prospective multi-center study. Crit Care Med 38(1):9-15, 2010.
33. Massion PB, Dive AM, Doyen C, Bulpa P, Jamart J, Bosly A, Installe E: Prognosis of hematologic malignancies does not predict intensive care unit mortality. Crit Care Med 30(10):2260-2270, 2002.
34. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, et al.: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 34(1):17-60, 2008.
35. Pene F, Percheron S, Lemiale V, Viallon V, Claessens YE, Marque S, Charpentier J, Angus DC, Cariou A, Chiche JD, et al.: Temporal changes in management and outcome of septic shock in patients with malignancies in the intensive care unit. Crit Care Med 36(3):690-696, 2008.